Genervon Biopharmaceuticals LLC
🇺🇸United States
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Genervon Biopharmaceuticals, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01854294
- Locations
- 🇺🇸
Columbia Medical Center NY, New York, New York, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Genervon Biopharmaceuticals, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01850381
- Locations
- 🇺🇸
Columbia University Medical Center/NY Presbyterian Hospital, New York, New York, United States
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Genervon Biopharmaceuticals, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01221246
- Locations
- 🇺🇸
Huntington Memorial Hospital Stroke Center, Pasadena, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸California Pacific Medical Center Research Institute, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath